Strata Critical Medical, Inc. (Nasdaq: SRTA) has completed the acquisition of Keystone Perfusion Services LLC, a major organ recovery and medical solutions provider.
Keystone is projected to generate around $65 million in revenue and $13 million in Adjusted EBITDA in 2025, with revenue growth exceeding 50% from 2024.
The acquisition enhances Strata's service offerings, positioning it as a comprehensive organ transplant service provider.
Acquisition Impact
Keystone's acquisition expands Strata's capabilities, enabling direct provision of critical services to transplant customers and entry into non-transplant medical sectors.
Financial Insights
The $124 million acquisition represents a 9x multiple of Keystone's estimated 2025 Adjusted EBITDA of $13 million, with a focus on generating Free Cash Flow conversion of approximately 80%.
Market Expansion
Keystone's non-transplant services open new market opportunities for Strata, with potential for significant organic and inorganic growth within fragmented medical sectors.
- The acquisition of Keystone positions Strata as a leading full-service organ transplant provider with expanded capabilities in surgical recovery and perfusion services.
- Keystone's expertise in NRP and recovery services enhances Strata's ability to provide comprehensive solutions to healthcare customers nationwide.
- The transaction strengthens Strata's position in the medical sector, setting the stage for enhanced growth and operational efficiencies across multiple service areas.
The acquisition of Keystone Perfusion Services marks a significant strategic move for Strata Critical Medical, Inc., solidifying its position as a key player in the organ recovery and medical solutions industry.